Related Experiment Video
Updated: May 27, 2025
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.6K
Antidopaminergic medications in Huntington's disease
Andrew M Tan1,2, Michal Geva1, Y Paul Goldberg1
1Prilenia Therapeutics B.V., Naarden, The Netherlands.
Journal of Huntington'S Disease
|February 20, 2025
Summary
Antidopaminergic medications (ADMs) manage Huntington's disease (HD) symptoms but may worsen cognitive and functional measures. Careful monitoring and consideration in clinical trials are crucial for accurate HD progression assessment.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder with motor, cognitive, and behavioral symptoms.
- Antidopaminergic medications (ADMs) are frequently used to manage these symptoms, improving daily life for patients and caregivers.
- The overall impact of ADM use on HD progression and clinical trial outcomes remains unclear.
Purpose of the Study:
- To review the role of ADMs in managing Huntington's disease.
- To assess the symptomatic benefits and potential risks associated with ADM use in HD.
- To emphasize the need to consider ADM effects in clinical trial design and interpretation.
Main Methods:
- Systematic review of existing literature on ADM use in Huntington's disease.
- Analysis of evidence regarding ADM effects on cognitive function, functional impairment, and disease progression.
- Evaluation of ADM side effects, drug interactions (e.g., CYP2D6 inhibitors), and dose-dependent risks.
Main Results:
- ADMs offer symptomatic benefits for HD motor and behavioral disturbances.
- Evidence suggests ADMs may be associated with worse cognitive and functional outcomes in HD patients.
- Potential for ADM side effects to mimic or exacerbate HD symptoms in clinical assessments.
Conclusions:
- Clinical trial designs for HD interventions must account for concomitant ADM use.
- Standardized scales like the Unified Huntington's Disease Rating Scale should consider ADM impact.
- Individualized dose monitoring of ADMs is essential for effective clinical care and research in HD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
242
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
242
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
118
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
118
01:15Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429
01:23Antidepressant Drugs: MAOIs and Other Agents
181
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
181